Literature DB >> 8481213

Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?

R Scaletscky1, J A Smith.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8481213     DOI： 10.2165/00002018-199308040-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  22 in total

1.  Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.

Authors:  A V Kaisary; C J Tyrrell; W B Peeling; K Griffiths
Journal:  Br J Urol       Date:  1991-05

2.  LHRH agonists--mechanism of action and effect on target tissues.

Authors:  J Sandow; B Beier
Journal:  Prog Clin Biol Res       Date:  1985

3.  Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma.

Authors:  J G Klign; H J de Voogt; F H Schröder; F H de Jong
Journal:  Lancet       Date:  1985-08-31       Impact factor: 79.321

4.  Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.

Authors:  J A Smith
Journal:  J Urol       Date:  1984-06       Impact factor: 7.450

5.  Priapism in hypogonadal men receiving gonadotropin releasing hormone.

Authors:  R K Whalen; R W Whitcomb; W F Crowley; F J McGovern
Journal:  J Urol       Date:  1991-05       Impact factor: 7.450

Review 6.  Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

Authors:  I M Thompson; E J Zeidman; F R Rodriguez
Journal:  J Urol       Date:  1990-12       Impact factor: 7.450

7.  Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

8.  DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate.

Authors:  B S Stein; J A Smith
Journal:  Urology       Date:  1985-04       Impact factor: 2.649

9.  Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.

Authors:  F H Schroeder; T M Lock; D R Chadha; F M Debruyne; H F Karthaus; F H de Jong; J G Klijn; A W Matroos; H J de Voogt
Journal:  J Urol       Date:  1987-05       Impact factor: 7.450

10.  The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.

Authors:  J Trachtenberg
Journal:  J Urol       Date:  1983-06       Impact factor: 7.450
View more
  1 in total

Review 1.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.